Raymond James Financial Services Advisors Inc. raised its holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 19.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,310 shares of the company’s stock after purchasing an additional 548 shares during the quarter. Raymond James Financial Services Advisors Inc. owned 0.07% of VanEck Pharmaceutical ETF worth $261,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of PPH. Bank of America Corp DE boosted its holdings in shares of VanEck Pharmaceutical ETF by 161.4% during the 1st quarter. Bank of America Corp DE now owns 778,144 shares of the company’s stock valued at $60,407,000 after acquiring an additional 480,478 shares in the last quarter. Avalon Trust Co bought a new position in VanEck Pharmaceutical ETF during the 1st quarter worth $22,231,000. Goldman Sachs Group Inc. raised its position in VanEck Pharmaceutical ETF by 144.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 359,687 shares of the company’s stock worth $27,638,000 after purchasing an additional 212,560 shares during the last quarter. HRT Financial LP raised its position in VanEck Pharmaceutical ETF by 1,225.5% during the 1st quarter. HRT Financial LP now owns 67,098 shares of the company’s stock worth $5,208,000 after purchasing an additional 62,036 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in VanEck Pharmaceutical ETF during the 2nd quarter worth $4,464,000.
VanEck Pharmaceutical ETF Stock Up 0.5 %
Shares of NASDAQ:PPH opened at $76.55 on Friday. The firm has a market cap of $389.64 million, a P/E ratio of 16.59 and a beta of 0.72. VanEck Pharmaceutical ETF has a 12-month low of $71.27 and a 12-month high of $83.35. The business has a fifty day simple moving average of $79.81 and a 200 day simple moving average of $79.17.
VanEck Pharmaceutical ETF Announces Dividend
VanEck Pharmaceutical ETF Company Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
- Five stocks we like better than VanEck Pharmaceutical ETF
- How to Invest in Apparel Stocks
- MarketBeat Week in Review – 10/30 – 11/3
- 3 REITs to Buy and Hold for the Long Term
- Shocking uranium play that hedge funds kept hidden
- How to Effectively Use the MarketBeat Ratings Screener
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.